Jamil H. Muradov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jamil H. Muradov has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alon Friedman
Department of Medical Neuroscience and the Brain Repair Center, Faculty of Medicine, Dalhousie University, Halifax, Canada
1 shared publication - David B. Clarke
Department of Surgery (Neurosurgery), Dalhousie University, Halifax, Canada
1 shared publication - David O. Okonkwo
Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
1 shared publication Gerben Van Hameren
Department of Medical Neuroscience, Dalhousie University, Halifax, Canada
1 shared publication- Jens Peter Dreier
Center for Stroke Research Berlin – Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany
1 shared publication - Mark Alexander MacLean
Dalhousie University
1 shared publication
Latest Publications
- Open Access
- 15 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (50) , eadj2417
Memantine inhibits cortical spreading depolarization and improves neurovascular function following repetitive traumatic brain injury
Cortical spreading depolarization (CSD) is a promising target for neuroprotective therapy in traumatic brain injury (TBI). We explored the effect of NMDA receptor antagonism on electrically triggered CSDs in healthy and brain-injured animals. Rats received either one moderate or four daily repetitive mild closed head impacts (rmTBI). Ninety-three animals underwent craniectomy with electrocorticographic (ECoG) and local blood flow monitoring. In brain-injured animals, ketamine or memantine inhibited CSDs in 44 to 88% and 50 to 67% of cases, respectively. Near-DC/AC-ECoG amplitude was reduced by 44 to 75% and 52 to 67%, and duration by 39 to 87% and 61 to 78%, respectively. Daily memantine significantly reduced spreading depression and oligemia following CSD. Animals (N= 31) were randomized to either memantine (10 mg/kg) or saline with daily neurobehavioral testing. Memantine-treated animals had higher neurological scores. We demonstrate that memantine improved neurovascular function following CSD in sham and brain-injured animals. Memantine also prevented neurological decline in a blinded, preclinical randomized rmTBI trial.
- 15 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (50) , eadj2417
Open AccessMemantine inhibits cortical spreading depolarization and improves neurovascular function following repetitive traumatic brain injury
Cortical spreading depolarization (CSD) is a promising target for neuroprotective therapy in traumatic brain injury (TBI). We explored the effect of NMDA receptor antagonism on electrically triggered CSDs in healthy and brain-injured animals. Rats received either one moderate or four daily repetitive mild closed head impacts (rmTBI). Ninety-three animals underwent craniectomy with electrocorticographic (ECoG) and local blood flow monitoring. In brain-injured animals, ketamine or memantine inhibited CSDs in 44 to 88% and 50 to 67% of cases, respectively. Near-DC/AC-ECoG amplitude was reduced by 44 to 75% and 52 to 67%, and duration by 39 to 87% and 61 to 78%, respectively. Daily memantine significantly reduced spreading depression and oligemia following CSD. Animals (N= 31) were randomized to either memantine (10 mg/kg) or saline with daily neurobehavioral testing. Memantine-treated animals had higher neurological scores. We demonstrate that memantine improved neurovascular function following CSD in sham and brain-injured animals. Memantine also prevented neurological decline in a blinded, preclinical randomized rmTBI trial.